OCUL Stock Summary and Trading Ideas (Ocular Therapeutix | NASDAQ:OCUL)

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix trades on the NASDAQ stock market under the symbol OCUL.

As of March 6, 2026, OCUL stock price declined to $10.27 with 5,438,305 million shares trading.

OCUL has a beta of 0.92, meaning it tends to be less sensitive to market movements. OCUL has a correlation of 0.07 to the broad based SPY ETF.

OCUL has a market cap of $2.24 billion. This is considered a Mid Cap stock.

Last quarter Ocular Therapeutix reported $13 million in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.04.

In the last 3 years, OCUL traded as high as $16.44 and as low as $2.00.

The top ETF exchange traded funds that OCUL belongs to (by Net Assets): VTI, IWM, VXF, IWO, PJP.

OCUL has outperformed the market in the last year with a price return of +39.9% while the SPY ETF gained +18.7%. However, in the short term, OCUL had mixed performance relative to the market. It has underperformed in the last 3 months, returning -18.4% vs -1.7% return in SPY. But in the last 2 weeks, OCUL shares have fared better than the market returning +32.0% compared to SPY -2.5%.

OCUL support price is $9.69 and resistance is $10.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCUL shares will trade within this expected range on the day.